FindTrial
Sign In

LMP744

DRUG2 trials

Sponsors

National Cancer Institute (NCI), National Institute of Neurological Disorders and Stroke (NINDS)

Conditions

Brain CancerBrain and Central Nervous System TumorsGBMGlioblastoma IDH (Isocitrate Dehydrogenase) WildtypeGlioblastoma MultiformeGlioblastomasGliomaGlioma, Malignant

Phase 1

Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas
CompletedNCT03030417
National Cancer Institute (NCI)Lymphoma, Solid Tumors
Start: 2017-02-27End: 2023-10-12Updated: 2024-12-10
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
RecruitingNCT07416188
National Institute of Neurological Disorders and Stroke (NINDS)Brain and Central Nervous System Tumors, Brain Cancer, GBM +12
Start: 2026-07-15End: 2032-12-31Target: 40Updated: 2026-07-30

Related Papers

Phase 1 studies of the indenoisoquinolines LMP776 and LMP744 in patients with solid tumors and lymphomas
Cancer Chemotherapy and Pharmacology2025-05-291 citations
Phase 1 study of indenoisoquinoline LMP744 in adults with relapsed solid tumors and lymphomas.
Journal of Clinical Oncology2023-06-012 citations